This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (146)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Raymond A. Smego, Jr, MD; David T. Durack, MB, DPhil

Arch Intern Med. 1982;142(6):1183-1185.

Abstract
• The neuroleptic malignant syndrome (NMS) comprises hyperpyrexia, altered consciousness, muscular rigidity, and autonomic dysfunction. It is a rare idiosyncratic reaction to major tranquilizers, including the phenothiazines, butyrophenones, and thioxanthenes; haloperidol and fluphenazine enanthate or fluphenazine decanoate are the drugs most commonly incriminated. The syndrome occurs after therapeutic rather than toxic doses of neuroleptic drugs and is unrelated to the duration of therapy. The NMS is attributed to a disturbance of dopaminergic systems within the basal ganglia and hypothalamus. Associated laboratory abnormalities include leukocytosis, with elevated serum creatine phosphokinase (CPK) and liver enzyme concentrations. The NMS, which is known to some psychiatrists and neurologists but to few internists, probably is underdiagnosed; therefore, its true incidence is unknown. The NMS should be included in the differential diagnosis of any febrile patient with a history of neuroleptic treatment. Because the mortality of NMS is about 20%, early diagnosis and withdrawal of the neuroleptic drug therapy is crucial. Supportive treatment in a medical intensive care unit may be required.

(Arch Intern Med 1982;142:1183-1185)

Author Affiliations
From the Department of Medicine, Division of Infectious Diseases, Duke University Medical Center, Durham, NC.

Footnotes
Accepted for publication Feb 22, 1982.

Reprint requests to Duke University Medical Center, Box 31229, Durham, NC 27710 (Dr Smego).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Neuroleptic Malignant Syndrome in a Multiple Trauma Patient
Boorse and Rhodes
Arch Surg 1990;125:274-275.
ABSTRACT  

Neuroleptic Malignant Syndrome in a Child Treated With Metoclopramide for Chemotherapy-Related Nausea
Brower et al.
J Child Neurol 1989;4:230-232.
 

Metoclopramide-Induced Neuroleptic Malignant Syndrome
Friedman et al.
Arch Intern Med 1987;147:1495-1497.
ABSTRACT  

Disorders of Temperature Control: Hyperthermia, Part II
Curley and Irwin
J Intensive Care Med 1986;1:91-100.
ABSTRACT  

A Neuroleptic Malignantlike Syndrome due to Levodopa Therapy Withdrawal
Friedman et al.
JAMA 1985;254:2792-2795.
ABSTRACT  

Neuroleptic Malignant Syndrome: Successful Treatment With Pancuronium
Sangal and Dimitrijevic
JAMA 1985;254:2795-2796.
ABSTRACT  

Myoglobinuria in Neuroleptic Malignant Syndrome
Fink
Arch Intern Med 1985;145:1736-1736.
ABSTRACT  

Hypercalcemia in the Neuroleptic Malignant Syndrome
Wang et al.
Arch Intern Med 1985;145:143-144.
ABSTRACT  

Neuroleptic Malignant Syndrome Complicated by Disseminated Intravascular Coagulation
Eles et al.
Arch Intern Med 1984;144:1296-1297.
ABSTRACT  

Neuroleptic Malignant Syndrome and Dopaminergic Blockade
Hashimoto et al.
Arch Intern Med 1984;144:629-630.
ABSTRACT  

Neuroleptic Malignant Syndrome: Successful Treatment With Bromocriptine
Mueller et al.
JAMA 1983;249:386-388.
ABSTRACT